[HTML][HTML] Tumor microenvironment and metabolic remodeling in gemcitabine‐based chemoresistance of pancreatic cancer
Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
[引用][C] Tumor microenvironment and metabolic remodeling in gemcitabine‐based chemoresistance of pancreatic cancer
Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - cir.nii.ac.jp
Tumor microenvironment and metabolic remodeling in gemcitabine‐based chemoresistance
of pancreatic cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
of pancreatic cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
[PDF][PDF] Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer
Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - researchgate.net
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer.
Z Gu, Y Du, X Zhao, C Wang - Cancer Letters, 2021 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer
Z Gu, Y Du, X Zhao, C Wang - Cancer letters - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …